Investor Relations

Corporate Profile

Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering new approaches to treat obesity and T2D. Our Revita® and Rejuva® platform candidates are designed to target root causes of metabolic diseases and break the pattern of metabolic disease treatment from chronic management to potentially prevent and reverse metabolic disease. Fractyl Health is based in Burlington, Massachusetts.

Corporate Presentation

Minimum 15 minutes delayed. Source: LSEG

News Releases

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 12, 2024

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024

Fractyl Health to Participate in the Upcoming December Conferences

Nov 26, 2024

Events

Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024 | 11:19 PM EST

7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024 | 11:19 PM EST

SEC Filings

A statement of beneficial ownership of common stock by certain persons

Nov 14, 2024 | Form Type: SC 13G

Nov 14, 2024

A statement of beneficial ownership of common stock by certain persons

Nov 13, 2024 | Form Type: SC 13G

Nov 13, 2024

Investor Relations Contacts

Stephen Jasper

Gilmartin Group
Email: stephen@gilmartinir.com
Phone: 619.949.3681

Lisa Davidson, Chief Financial Officer

Email: IR@fractyl.com
Phone: 781.902.8800